analytical methods raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-23 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Delta waves, like all brain waves, can be detected by electroencephalography (EEG). Delta waves were originally defined as having a frequency between 1 and 4 Hz, although more recent classifications put the boundaries at between 0.5 and 2 Hz. They are the slowest and highest amplitude classically described brainwaves, although recent studies have described slower (<0.1 Hz) oscillations Delta waves begin to appear in stage 3 sleep, but by stage 4 nearly all spectral activity is dominated by delta waves. Stage 3 sleep is defined as having less than 50% delta wave activity, while stage 4 sleep has more than 50% delta wave activity. These stages have recently been combined and are now collectively referred to as stage N3 slow-wave sleep. During N3 SWS, delta waves account for 20% or more of the EEG record during this stage. Delta waves occur in all mammals, and potentially all animals as well. Delta waves are often associated with another EEG phenomenon, the K-complex. K-complexes have been shown to immediately precede delta waves in slow wave sleep. Delta waves have also been classified according to the location of the activity into frontal (FIRDA), temporal (TIRDA), and occipital (OIRDA) intermittent delta activity.
Carnivore protoparvovirus 1 is a species of parvovirus that infects carnivorans. It causes a highly contagious disease in both dogs and cats separately. The disease is generally divided into two major genogroups: the group of the classical feline panleukopenia virus (FPLV), and the group of the canine parvovirus type 2 (CPV-2), which appeared in the 1970s. Belonging to the family Parvoviridae, FPLV have linear, single-stranded DNA (ssDNA) genomes. This agent is one of the smallest animal viruses, barely 18 to 20 nm in diameter. Like other parvovirus genomes, it has hairpin structures at both ends of its genome: 3-genome Y-type structure and 5-terminal U-shaped structure, making it challenging to amplify the full-length genome of parvovirus despite its small size. Sequences in the genome show a high degree of nucleotide conservation in the VP2 gene after over 90 years since it has emerged; the VP2 gene codes for the capsid protein VP2, a main structural protein, which determines the major mutations during the evolution of CPV. FPLV is known to infect all wild and domestic members of the felid (cat) family worldwide. It is a highly contagious, severe infection that causes gastrointestinal, immune system, and nervous system disease. Its primary effect is to decrease the number of white blood cells, causing the disease known as feline panleukopenia. Although it was once thought that only FPLV caused panleukopenia in cats, it has been confirmed that a feline panleukopenia illness can be caused by CPV 2a, 2b, and 2c. FPLV is commonly referred to as:
=== As livestock feed === Mealworm has been investigated as a potential ingredient in livestock feed due to its high protein content and balanced amino acid profile, making it nutritionally suitable as a substitute for conventional protein sources such as fish meal or soybean meal. Although they can be raised in small spaces suitable for industrial production, life cycle assessment studies have shown that mealworm protein performs worse than soybean or fish meal protein in terms of energy use, greenhouse gas emissions, acidification and eutrophication.
== History == Pantoprazole was discovered by scientists at Byk Gulden, a subsidiary of Altana; the drug discovery program started in 1980, producing pantoprazole in 1985. The compound was actually created by chemists working to scale up a different chemical that had been chosen as a development candidate. Byk Gulden partnered with Smith Kline & French in 1984. The compound's development names were BY1029 and SK&F96022. By 1986 the companies had created the sodium salt, pantoprazole sodium sesquihydrate, and decided to develop it as it was more soluble and stable, and was more compatible with other ingredients used in the formulation. It was first marketed in Germany in 1994. Wyeth licensed the US patent from Altana, and obtained marketing approval from the US FDA in 2000 under the trade name Protonix. In 2004, worldwide sales of the drug were $3.65 billion, about half of which were in the US. In 2007, Altana's drug business was acquired by Nycomed. Nycomed was in turn acquired by Takeda in 2011 and Wyeth was acquired by Pfizer in 2009. The patent protecting the drug was set to expire in 2010, but Teva Pharmaceuticals filed an Abbreviated New Drug Application (ANDA) in 2007, and Wyeth and Nycomed sued Teva for patent infringement, but Teva decided to launch its generic drug "at risk" that year, before the patent had been invalidated. Wyeth launched an authorized generic in 2008. Pfizer and Takeda's patent exclusivity expired in 2010, and an administrative exclusivity they had for pediatric use expired in January 2011, and full generic competition began.
Sources: en.wikipedia.org
Blood accounts for 7% of the human body weight, with an average density around 1060 kg/m3, very close to pure water's density of 1000 kg/m3. The average adult has a blood volume of roughly 5 litres (11 US pt) or 1.3 gallons, which is composed of plasma and formed elements. The formed elements are the two types of blood cell or corpuscle – the red blood cells, (erythrocytes) and white blood cells (leukocytes) – and the cell fragments called platelets that are involved in clotting. By volume, the red blood cells constitute about 45% of whole blood, the plasma about 54.3%, and white cells about 0.7%.
Compared to traditional cigarettes, reusable e-cigarettes do not create waste and potential litter from every use in the form of discarded cigarette butts. Traditional cigarettes tend to end up in the ocean where they cause pollution, though once discarded they undergo biodegradation and photodegradation. A 2025 review in Nicotine & Tobacco Research concluded that the chemical, metallic and electrical composition of e-cigarettes could qualify them as hazardous and electronic waste, and recommended clear, enforceable disposal and recycling requirements, including manufacturer responsibility and consumer-facing recycling information, in jurisdictions where e-cigarettes are legally sold. E-cigarettes that are not reusable contribute to the problem of electronic waste, which can create a hazard for people and other organisms. If improperly disposed of, they can release heavy metals, nicotine, and other chemicals from batteries and unused e-liquid. A 2024 open-access study in Science of the Total Environment that dismantled nine popular disposable vapes reported a complex mix of plastics and metals, including toxic or potentially toxic elements such as lead and mercury, which the authors noted could pose environmental hazards through leaching after littering or landfilling. A July 2018–April 2019 garbology study found e-cigarette products composed 19% of the waste from all traditional and electronic tobacco and cannabis products collected at 12 public high schools in Northern California.
Fire was used by the Lower Paleolithic hominins Homo erectus and Homo ergaster as early as 300,000 to 1.5 million years ago and possibly even earlier by the early Lower Paleolithic (Oldowan) hominin Homo habilis or by robust Australopithecines such as Paranthropus. However, the use of fire only became common in the societies of the following Middle Stone Age and Middle Paleolithic. Use of fire reduced mortality rates and provided protection against predators. Early hominins may have begun to cook their food as early as the Lower Paleolithic (c. 1.9 million years ago) or at the latest in the early Middle Paleolithic (c. 250,000 years ago). Some scientists have hypothesized that hominins began cooking food to defrost frozen meat, which would help ensure their survival in cold regions. Archaeologists cite morphological shifts in cranial anatomy as evidence for emergence of cooking and food processing technologies. These morphological changes include decreases in molar and jaw size, thinner tooth enamel, and decrease in gut volume. During much of the Pleistocene epoch, our ancestors relied on simple food processing techniques such as roasting. The Upper Palaeolithic saw the emergence of boiling, an advance in food processing technology which rendered plant foods more digestible, decreased their toxicity, and maximised their nutritional value. Thermally altered rock (heated stones) are easily identifiable in the archaeological record.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.